Ascendis Pharma A/S $ASND Stock Purchased by USS Investment Management Ltd

USS Investment Management Ltd boosted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 21.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 170,587 shares of the biotechnology company’s stock after acquiring an additional 29,577 shares during the period. USS Investment Management Ltd’s holdings in Ascendis Pharma A/S were worth $38,878,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Perceptive Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 41.6% in the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after buying an additional 450,000 shares during the period. Sei Investments Co. grew its position in shares of Ascendis Pharma A/S by 24.8% during the first quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock worth $80,318,000 after buying an additional 69,673 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Ascendis Pharma A/S by 27.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 227,013 shares of the biotechnology company’s stock worth $51,602,000 after buying an additional 48,275 shares in the last quarter. Frazier Life Sciences Management L.P. grew its position in shares of Ascendis Pharma A/S by 68.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock worth $60,053,000 after buying an additional 91,822 shares in the last quarter. Finally, Orbimed Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 5.8% during the first quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company’s stock worth $41,624,000 after buying an additional 10,000 shares during the period.

Ascendis Pharma A/S Stock Down 5.3%

Shares of NASDAQ ASND opened at $255.96 on Friday. The business has a 50-day moving average of $242.80 and a two-hundred day moving average of $240.70. The company has a market capitalization of $15.97 billion, a price-to-earnings ratio of 16.73 and a beta of 0.40. Ascendis Pharma A/S has a 1 year low of $188.08 and a 1 year high of $282.15. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.89 and a quick ratio of 2.29.

Insider Transactions at Ascendis Pharma A/S

In other news, EVP Anni Lotte Kirstine S. Pedersen sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $263.89, for a total transaction of $5,277,800.00. Following the sale, the executive vice president owned 19,460 shares of the company’s stock, valued at approximately $5,135,299.40. This trade represents a 50.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mads Bodenhoff sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the sale, the senior vice president directly owned 3,000 shares in the company, valued at $810,570. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 40.00% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ASND shares. Weiss Ratings raised shares of Ascendis Pharma A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, November 13th. Stifel Nicolaus decreased their price target on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Cantor Fitzgerald boosted their price target on shares of Ascendis Pharma A/S from $300.00 to $315.00 and gave the stock an “overweight” rating in a report on Friday, November 13th. KeyCorp set a $330.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 13th. Finally, Barclays increased their price objective on shares of Ascendis Pharma A/S from $329.00 to $341.00 and gave the company an “overweight” rating in a research report on Monday. Nineteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $312.67.

Read Our Latest Stock Report on Ascendis Pharma A/S

Ascendis Pharma A/S Profile

(Free Report)

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

Further Reading

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Free Report).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.